Gonasi Hp

Gonasi Hp is a prescription injectable medication that contains the hormone chorionic gonadotropin (hCG) as its active ingredient. It is supplied as a sterile solution for intramuscular or subcutaneous injection and is marketed in the European Union. Classified as a gonadotropin, Gonasi Hp mimics luteinizing hormone by binding LH receptors to stimulate ovulation and support the luteal phase in assisted reproductive protocols and certain pediatric endocrine treatments.

Gonasi Hp is indicated for several reproductive and endocrine indications under medical supervision.

- Induction of ovulation in women with anovulatory infertility. - Support of the luteal phase during assisted reproductive technology cycles. - Treatment of infertility associated with luteinizing hormone deficiency. - Management of cryptorchidism in male infants. - Adjunct therapy for certain cases of hypogonadism. - Facilitation of sperm production in men with hypogonadotropic hypogonadism.

Adverse reactions to Gonasi Hp may vary in frequency and severity.

Common: - Injection site pain, redness, or swelling. - Headache. - Nausea or mild gastrointestinal discomfort. - Fatigue or mild dizziness. - Mood changes such as irritability. - Mild flu-like symptoms.

Serious: - Ovarian hyperstimulation syndrome (OHSS). - Allergic reactions including rash, itching, or anaphylaxis. - Thromboembolic events. - Rapid weight gain due to fluid retention. - Severe abdominal pain. - Severe hypertension. - Life‑threatening anaphylactic reaction.

Before prescribing Gonasi Hp, clinicians should consider several precautionary factors to ensure safe use.

- Assess for contraindications such as active ovarian cysts or uncontrolled thyroid disease. - Evaluate the patient’s risk for ovarian hyperstimulation syndrome, especially in assisted reproduction. - Review history of allergic reactions to hCG or any component of the formulation. - Monitor for signs of thromboembolic disorders in patients with clotting risk factors. - Use caution in patients with cardiovascular disease or hypertension. - Adjust dosing in pediatric patients treated for cryptorchidism under specialist guidance. - Avoid use during pregnancy unless specifically indicated for luteal support.

Gonasi Hp may interact with other medications or substances that affect hormonal balance or coagulation.

Avoid: - Concurrent use of estrogen‑containing contraceptives, which may reduce hCG efficacy. - Medications that increase the risk of thrombosis, such as hormonal therapy or certain chemotherapy agents. - High‑dose corticosteroids, which may mask allergic reactions.

Use with caution: - Anticoagulants, as hCG can influence clotting factors. - Thyroid hormone replacement, because hCG can affect thyroid function tests. - Other gonadotropins, requiring careful dose adjustment and monitoring. - GnRH analogues, as combined therapy may alter ovulation response. - Other hormonal agents, necessitating close clinical supervision.